Glioblastoma. Part II: Future directions.

Missouri medicine

Volumn 108, Issue 4, 2011, Pages 289-291

  Salacz, Michael E ^a   Watson, Kenneth R ^b   Schomas, David A ^b  

^a Saint Luke's Brain and Stroke Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN TUMOR; DRUG EFFECT; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INTRAARTERIAL DRUG ADMINISTRATION; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRA-ARTERIAL; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; RADIATION ONCOLOGY; STANDARD OF CARE;

EID: 80054782128     PISSN: 00266620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)